More than a decade of innovation
STADA has been a key player in the biosimilars industry for almost 20 years, with a focus on product research and development.
Our sales company, cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH, introduces the Group's first biosimilar for the treatment of anemia casued by chronic kidney failure and chemotherapy. In Germany, it is marketed under the brand name Silapo®.
We expand our biosimilar portfolio through licensing the filgrastim preparation Grastofil®.
We expand our biosimilar portfolio by in-licensing a biosimilar for the indication of osteoporosis. The product was launched in August 2019 following the successful development and the patent protection expiration of the reference product.
STADA becomes majority shareholder of BIOCEUTICALS Arzneimittel AG, which creates an excellent basis for growth in biosimilars.
STADA becomes shareholder of Xbrane Biopharma, a Swedish company developing biosimilars.
The launch of the Teriparatide biosimilar Movymia® in August, is another important addition to STADA's biosimilar portfolio in Europe.